Drug name - Neupro

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617591 UCB INC Transdermal delivery system for the administration of rotigotine Jul, 2023

(9 months from now)

US8246980 UCB INC Transdermal delivery system Nov, 2025

(3 years from now)

US8246979 UCB INC Transdermal delivery system for the administration of rotigotine Sep, 2027

(4 years from now)

US10350174 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine Dec, 2030

(8 years from now)

US10130589 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine Dec, 2030

(8 years from now)

US9925150 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine Mar, 2032

(9 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; treatment of restless legs syndrome by application of claimed transdermal delivery system

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
1MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
2MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
3MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
4MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
6MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
8MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.